Summit Therapeutics widens loss as drug development continues
(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its financial results for the third quarter to 31 October on Thursday. The AIM-traded firm had cash and cash equivalents at period end of £34.6m compared to £16.3m on 31 January. Its loss for the nine months was £1
Read more